Protocols

The available literature on epithalon (epitalon) consists primarily of preclinical studies and does not provide standardized clinical dosing protocols. The research is limited to laboratory investigations in cell cultures and animal models.

Reported Research Protocols

The published studies have used epithalon in experimental settings but do not establish clinical dosing guidelines:

In vitro studies: Research has examined epithalon's effects on mouse oocytes, neuronal differentiation of stem cells, and skin fibroblast functions in laboratory conditions
Preclinical investigations: Studies have explored the peptide's role in neurogenesis and gene expression regulation in animal models
Peptide identification: Researchers have isolated and characterized the AEDG peptide sequence from pineal gland extracts

Limitations of Current Evidence

The existing literature has significant limitations regarding clinical protocols:

No established human dosing: Published studies do not report standardized dosing regimens for human use
Lack of clinical trials: No controlled clinical trials were identified that would inform therapeutic protocols
Research-only applications: Current evidence is restricted to laboratory and preclinical research contexts

Important Considerations

The research suggests epithalon may have biological activity related to cellular aging and neurogenesis, but the evidence base is insufficient to determine appropriate clinical dosing, administration routes, treatment duration, or safety parameters for human use.

Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. The current evidence does not support established clinical protocols for epithalon use in humans. Consult with a qualified healthcare provider before considering any peptide therapy.

Epithalon (Epitalon)

Member access required